Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective
- 27 September 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 2801-2809
Abstract
Breast cancer is the most common cause of cancer death in women and presents a serious therapeutic challenge worldwide. Traditional treatments are less successful at targeting cancer tumors, leading to recurrent treatment‐resistant secondary malignancies. Oncolytic virotherapy (OV) is a novel anticancer strategy with therapeutic implications at targeting cancer cells by using mechanisms that differ from conventional therapies. Administration of OVs either alone or in combination with standard therapies provide new insights regarding the effectiveness and improvement of treatment responses for breast cancer patients. This review summarizes cellular, animal and clinical studies investigating therapeutic potency of oncolytic virotherapy in breast cancer treatment for a better understanding and hence a better management of this disease.Keywords
Funding Information
- Mashhad University of Medical Sciences (951860)
This publication has 77 references indexed in Scilit:
- Treatment of breast cancer stem cells with oncolytic herpes simplex virusCancer Gene Therapy, 2012
- Breast cancer stem cellsThe International Journal of Biochemistry & Cell Biology, 2012
- Oncolytic Herpes Simplex Virus 1 Encoding 15-Prostaglandin Dehydrogenase Mitigates Immune Suppression and Reduces Ectopic Primary and Metastatic Breast Cancer in MiceJournal of Virology, 2011
- Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble Transforming Growth Factor- β Receptor II–Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse ModelHuman Gene Therapy, 2010
- A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFβ signaling for breast cancer therapyCancer Gene Therapy, 2009
- Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cellsProceedings of the National Academy of Sciences, 2009
- Oncolytic Reovirus Effectively Targets Breast Cancer Stem CellsMolecular Therapy, 2009
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitorsCancer Treatment Reviews, 2009
- Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2Journal of Virology, 2008
- A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2/neu Enters Cells through the Mammary Tumor Receptor, Independently of the gD ReceptorsJournal of Virology, 2006